Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3452-3461

  Volante, Marco ^a   Terzolo, Massimo ^a   Fassnacht, Martin ^b   Rapa, Ida ^a   Germano, Antonina ^a   Sbiera, Silviu ^b   Daffara, Fulvia ^a   Sperone, Paola ^a   Scagliotti, Giorgio ^a   Allolio, Bruno ^b   Papotti, Mauro ^a   Berruti, Alfredo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG SENSITIVITY; EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 GENE; FEMALE; GENE; GENE EXPRESSION; GERMANY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ITALY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASE LARGE SUBUNIT 1 GENE; UPREGULATION;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; MITOTANE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84862546157     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2692     Document Type: Article

References (43)

1. Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol 2010;37:619-26.
2. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol 2008;61:787-93. (Pubitemid 351969722)
3. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010;58:609-15.
4. Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010;57:873-8.
5. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008;15:221-6. (Pubitemid 351595185)
6. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-66. (Pubitemid 41482999)
7. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 2010;17:797-807.
8. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma.N Engl J Med 2007;356:2372-80. (Pubitemid 46883771)
9. Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 2010;28:e401-2.
10. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92:148-54.
11. Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 2009;55:535-43.
12. Giordano TJ. The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. Am J Surg Pathol 2011;35:471-3.
13. Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010;70:8276-81.
14. Volante M, Sperone P, Bollito E, Frangipane E, Rosas R, Daffara F, et al. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 2006;19:1563-9. (Pubitemid 44789924)
15. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 2009;16:919-28.
16. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010;95:E161-71.
17. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009;27:1108-15.
18. Ragazzon B, Assié G, Bertherat J. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer 2011;18:R15-27.
19. Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 2009;16:907-18.
20. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-51. (Pubitemid 24140681)
21. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385-92. (Pubitemid 32947821)
22. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, et al. Plasma concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011;96:1844-51.
23. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009;27:4619-29.
24. Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010;28:1534-9.
25. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008;14:1059-64. (Pubitemid 351302551)
26. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25. (Pubitemid 44884058)
27. Jordheim LP, Sève P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011;12:693-702.
28. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011;7:323-35.
29. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37. (Pubitemid 43854976)
30. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6. (Pubitemid 19081702)
31. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009;115:243-50.
32. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96. (Pubitemid 44546920)
33. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer-use and controversy. N Engl J Med 2007;356:2415-8. (Pubitemid 46883778)
34. Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant mitotane for adrenocortical cancer-working through uncertainty. J Clin Endocrinol Metab 2009;94:1879-80.
35. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010;95:4925-32.
36. Wängberg B, Khorram-Manesh A, Jansson S, Jansson S, Nilsson B, Nilsson O, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010;17:265-72.
37. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6:386-94. (Pubitemid 40561415)
38. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophe-nyl)-1,1- dichloroethane (DDD or TDE). Arch Pathol 1949;48:387-94.
39. Vilar O, Tullner WW. Effects of o,p′DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 1959;65:80-6.
40. Cerquetti L, Sampaoli C, Amendola D, Bucci B, Misiti S, Raza G, et al. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cicli B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int J Oncol 2010;37:493-501.
41. Lund BO, Bergman A, Brandt I. In vitro macromolecular binding of 2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane (o,p′-DDD) in the mouse lung and liver. Chem Biol Interact 1989;70:63-72 (Pubitemid 19161215)
42. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-25. (Pubitemid 38365223)
43. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010;17:445-53.